Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

CAISMOV24, a new human low-grade serous ovarian carcinoma cell line

Full text
Author(s):
da Silva, Rodrigo Fernandes [1] ; Cardozo, Daniela Maira [1] ; Libanio Rodrigues, Gisele Olinto [2, 3] ; de Souza-Araujo, Caroline Natania [1] ; Migita, Natacha Azussa [2, 3] ; Lucci de Angelo Andrade, Liliana Aparecida [1] ; Derchain, Sophie [1, 4] ; Yunes, Jose Andres [1, 3] ; Guimaraes, Fernando [1, 4]
Total Authors: 9
Affiliation:
[1] Univ Estadual Campinas, Fac Ciencias Med, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Inst Biol, Campinas, SP - Brazil
[3] Ctr Infantil Boldrini, Lab Biol Mol, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Womens Hosp Prof Doutor Jose Aristodemo Pinotti C, Rua Alexander Fleming 101, BR-13083881 Campinas, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: BMC CANCER; v. 17, NOV 13 2017.
Web of Science Citations: 0
Abstract

Background: The spontaneous immortalization of primary malignant cells is frequently assigned to their genetic instability during in vitro culturing. In this study, the new epithelial ovarian cancer cell line CAISMOV24 was described and compared with its original low-grade serous ovarian carcinoma. Methods: The in vitro culture was established with cells isolated from ascites of a 60-year-old female patient with recurrent ovarian cancer. The CAISMOV24 line was assessed for cell growth, production of soluble biomarkers, expression of surface molecules and screened for typical mutations found in serous ovarian carcinoma. Additionally, comparative genomic hybridization was employed to compare genomic alterations between the CAISMOV24 cell line and its primary malignant cells. Results: CAISMOV24 has been in continuous culture for more than 30 months and more than 100 in vitro passages. The cell surface molecules EpCAM, PVR and CD73 are overexpressed on CAISMOV24 cells compared to the primary malignant cells. CAISMOV24 continues to produce CA125 and HE4 in vitro. Although the cell line had developed alongside the accumulation of genomic alterations (28 CNV in primary cells and 37 CNV in CAISMOV24), most of them were related to CNVs already present in primary malignant cells. CAISMOV24 cell line harbored KRAS mutation with wild type TP53, therefore it is characterized as low-grade serous carcinoma. Conclusion: Our results corroborate with the idea that genomic alterations, depicted by CNVs, can be used for subtyping epithelial ovarian carcinomas. Additionally, CAISMOV24 cell line was characterized as a low-grade serous ovarian carcinoma, which still resembles its primary malignant cells. (AU)

FAPESP's process: 11/14520-0 - Natural Killer cell-mediated targeting of human ovarian cancer and possibilities for immunotherapy
Grantee:Fernando Guimarães
Support type: Regular Research Grants
FAPESP's process: 16/07822-4 - Analysis of molecular biomarkers associated to chemoresistance derived from breast cancer stem cells
Grantee:Sophie Françoise Mauricette Derchain
Support type: Regular Research Grants
FAPESP's process: 14/07401-3 - Interaction of T-reg and NK lymphocytes from ovarian cancer patients during cytotoxic activity against ovarian neoplasia
Grantee:Rodrigo Fernandes da Silva
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 12/12802-1 - Cooperating mutations, functional studies and antibodies against the mutant IL7R in acute lymphoblastic leukemia
Grantee:José Andrés Yunes
Support type: Regular Research Grants